3F8.F · Q-linea AB (publ)

-

Please sign in to comment on 3F8.F

1 Comment

Admin

4 years, 2 months ago

Q-linea AB (publ) is currently in a long term downtrend where the price is trading 6.8% below its 200 day moving average.

From a valuation standpoint, the stock is 12.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1479.4.

Q-linea AB (publ)'s total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has increased by 21.5% to $-49M since the same quarter in the previous year.

Finally, its free cash flow fell by 40.1% to $-78M since the same quarter in the previous year.

Based on the above factors, Q-linea AB (publ) gets an overall score of 1/5.

Sector	Healthcare
Exchange	F
CurrencyCode	EUR
ISIN	SE0011527845
Industry	Medical Devices

Market Cap	341M
PE Ratio	0.0
Target Price	None
Beta	0.98
Dividend Yield	None

ABOUT

Q-linea AB (publ)

Q-linea AB (publ) engages in the development of instruments and consumables for infection disease diagnostics in the United Kingdom. The company offers ASTar, an antimicrobial susceptibility testing technologies used in the treatment of bloodstream infections and sepsis. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. It serves to physicians, hospitals, laboratories, healthcare payers and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

3F8.F · Q-linea AB (publ)

-

Q-linea AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Q-linea AB (publ) using a moving average strategy